Clinical trials of hypnotics.
This article reviews the clinical literature of flurazepam, temazepam, and triazolam. The long half-life drug flurazepam and the short half-life drug triazolam produced similar results in terms of clinical improvement and adverse effects when equivalent dosages were administered. Temazepam, in the present U.S. formulation, appeared to be less effective in sleep latency than the other two compounds.
D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005479:Flurazepam / Q000009:adverse effects / Q000627:therapeutic use*; D006207:Half-Life; D006801:Humans; D011597:Psychomotor Performance / Q000187:drug effects; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D013693:Temazepam / Q000009:adverse effects / Q000627:therapeutic use*; D014229:Triazolam / Q000009:adverse effects / Q000627:therapeutic use*
D014151:Anti-Anxiety Agents; D014229:Triazolam; D013693:Temazepam; D005479:Flurazepam